Onelar (Duloxetine)

Duloxetine acts on neurotransmitter pathways that influence mood and pain perception.

• Major depressive disorder: alleviates depressive symptoms and improves functional outcomes.
• Generalized anxiety disorder: reduces anxiety levels and associated physical symptoms.
• Diabetic peripheral neuropathic pain: lessens pain intensity and improves quality of life.
• Fibromyalgia: decreases widespread musculoskeletal pain and fatigue.
• Chronic musculoskeletal pain: provides relief from chronic lower‑back and osteoarthritis pain.

• Duloxetine inhibits the reuptake of serotonin and norepinephrine at central nervous system synapses, increasing the availability of these neurotransmitters in the synaptic cleft. This dual inhibition modulates pain signaling pathways and mood regulation circuits, contributing to its antidepressant and analgesic effects.

Duloxetine may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Dry mouth: reduced salivation.
• Headache: transient cranial pain.
• Sweating: increased perspiration.
• Fatigue: feeling of tiredness.
• Dizziness: light‑headed sensation.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Hypertensive crisis: sudden, severe increase in blood pressure.
• Serotonin syndrome: agitation, hyperthermia, and neuromuscular abnormalities.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Suicidal thoughts: emergence or worsening of suicidal ideation.
• Orthostatic hypotension: marked drop in blood pressure upon standing.

When prescribing Duloxetine, clinicians should evaluate patient history and monitor for specific safety concerns.

• Liver function: assess baseline enzymes and monitor periodically.
• Blood pressure: check regularly, especially in patients with hypertension.
• Suicide risk: monitor mood changes, particularly at treatment initiation.
• Drug discontinuation: taper gradually to avoid discontinuation syndrome.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Duloxetine can interact with several drug classes, requiring careful review of a patient’s medication list.

Major Interactions (Avoid)

• MAO inhibitors: risk of serotonin syndrome; a 14‑day washout is required.
• SSRIs/SNRIs: additive serotonergic effect may precipitate serotonin syndrome.
• Strong CYP1A2 inhibitors (e.g., fluvoxamine): increase duloxetine plasma levels.

Moderate Interactions (Monitor Closely)

• NSAIDs and antiplatelet agents: heightened bleeding risk.
• Antihypertensives: possible attenuation of blood‑pressure‑lowering effect.
• CYP2D6 substrates (e.g., metoprolol): duloxetine may raise their concentrations.